Abstract | PATIENT: OBJECTIVE: Unusual or unexpected effect of treatment. BACKGROUND: CASE REPORT: An insulin-dependent type 2 diabetic patient with multiple diabetic complications was placed on the combination of liraglutide and canagliflozin and 4 weeks later was able to discontinue insulin. In addition, in spite of discontinuing insulin, his HbA1c dropped from 7.0% to 6.8%, and he had reductions in body (weight from 247 to 218 lbs), BMI (from 34 to 29.5 Kg/m(2)), waist circumference (from 47 to 44 ½ inches), and neck circumference (from 19 ½ to 18 ¼ inches). CONCLUSIONS: The combination of an SGLT2 inhibitor and an incretin mimetic/analog results in improved glycemic control accompanied by significant weight loss. This combination needs to be studied in a prospective randomized trial because the effect of each of the components of this combination is synergistically magnified by the addition of the partner drug.
|
Authors | David S H Bell |
Journal | The American journal of case reports
(Am J Case Rep)
Vol. 15
Pg. 152-4
( 2014)
ISSN: 1941-5923 [Electronic] United States |
PMID | 24753783
(Publication Type: Journal Article)
|